换一批
换一批Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
作者：
Maheshi N,Ramasamy [1]
;
Angela M,Minassian [2]
;
Katie J,Ewer [2]
;
Amy L,Flaxman [2]
;
Pedro M,Folegatti [2]
;
Daniel R,Owens [3]
;
Merryn,Voysey [4]
;
Parvinder K,Aley [4]
;
Brian,Angus [2]
;
Gavin,Babbage [2]
;
Sandra,Belij-Rammerstorfer [2]
;
Lisa,Berry [3]
;
Sagida,Bibi [4]
;
Mustapha,Bittaye [2]
;
Katrina,Cathie [5]
;
Harry,Chappell [3]
;
Sue,Charlton [6]
;
Paola,Cicconi [2]
;
Elizabeth A,Clutterbuck [7]
;
Rachel,Colin-Jones [4]
;
Christina,Dold [7]
;
Katherine R W,Emary [4]
;
Sofiya,Fedosyuk [2]
;
Michelle,Fuskova [2]
;
Diane,Gbesemete [3]
;
Catherine,Green [8]
;
Bassam,Hallis [6]
;
Mimi M,Hou [2]
;
Daniel,Jenkin [2]
;
Carina C D,Joe [2]
;
Elizabeth J,Kelly [9]
;
Simon,Kerridge [4]
;
Alison M,Lawrie [2]
;
Alice,Lelliott [4]
;
May N,Lwin [3]
;
Rebecca,Makinson [2]
;
Natalie G,Marchevsky [4]
;
Yama,Mujadidi [4]
;
Alasdair P S,Munro [3]
;
Mihaela,Pacurar [3]
;
Emma,Plested [4]
;
Jade,Rand [3]
;
Thomas,Rawlinson [2]
;
Sarah,Rhead [7]
;
Hannah,Robinson [10]
;
Adam J,Ritchie [2]
;
Amy L,Ross-Russell [3]
;
Stephen,Saich [3]
;
Nisha,Singh [4]
;
Catherine C,Smith [4]
;
Matthew D,Snape [4]
;
Rinn,Song [11]
;
Richard,Tarrant [8]
;
Yrene,Themistocleous [2]
;
Kelly M,Thomas [6]
;
Tonya L,Villafana [12]
;
Sarah C,Warren [3]
;
Marion E E,Watson [2]
;
Alexander D,Douglas [13]
;
Adrian V S,Hill [13]
;
Teresa,Lambe [13]
;
Sarah C,Gilbert [13]
;
Saul N,Faust [14]
;
Andrew J,Pollard [7]
;
Oxford COVID Vaccine Trial Group
作者单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: maheshi.ramasamy@paediatrics.ox.ac.uk.
[1]
The Jenner Institute, University of Oxford, Oxford, UK.
[2]
NIHR Clinical Research Facility, University Hospital Southampton NHS Trust, Southampton, UK.
[3]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
[4]
Paediatric Medicine, University of Southampton, Southampton, UK.
[5]
National Infection Service, Public Health England, Porton Down, Salisbury, UK.
[6]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
[7]
Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK.
[8]
AstraZeneca BioPharmaceuticals Research and Development, Washington, DC, USA.
[9]
Nuffield Department of Medicine, and Oxford Centre for Clinical Tropical Medicine and Global Health, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
[10]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
[11]
AstraZeneca BioPharmaceuticals Research and Development, Bethesda, MA, USA.
[12]
The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
[13]
NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Trust and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
[14]
主题词
青少年(Adolescent);成年人(Adult);年龄因素(Age Factors);老年人(Aged);老年人, 80以上(Aged, 80 and over);女(雌)性(Female);人类(Humans);免疫接种, 加强(Immunization, Secondary);免疫球蛋白G(Immunoglobulin G);男(雄)性(Male);中年人(Middle Aged);单盲法(Single-Blind Method);青年人(Young Adult)
DOI
10.1016/S0140-6736(20)32466-1
PMID
33220855
发布时间
2023-11-15
- 浏览249
Lancet (London, England)
Lancet (London, England)
1979-1993页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
